| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Fred Hutchinson Cancer Research Center and 2 Department of Epidemiology, Seattle, Washington
Requests for reprints: Cornelia M. Ulrich, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M4-B402, Seattle, WA 98109-1024. Phone: 206-667-7617; Fax: 206-667-7850. E-mail: nulrich{at}fhcrc.org
Prostaglandin H synthase 2 (PTGS2) or cyclooxygenase-2 (COX-2) has been shown to play a key role in the regulation of inflammation, and its inhibition is associated with a reduced risk of colon cancer. The PTGS2 (COX-2) –765G > C promoter variant is located in a putative SP1 binding site and reduces PTGS2 expression. In a Minnesota-based case-control study of cases with adenomatous (n = 494) or hyperplastic polyps (n = 186) versus polyp-free controls (n = 584), we investigated the role of the PTGS2 –765G > C promoter polymorphism. Multiple logistic regression analysis was used, adjusting for age, body mass index, caloric intake, alcohol, fiber, sex, hormone use, and smoking. For colorectal adenoma, odds ratios (OR) compared with PTGS2 –765GG as reference were GC 1.00 [95% confidence interval (95% CI), 0.74-1.35] and CC 0.53 (95% CI, 0.22-1.28). For hyperplastic polyps, the comparable adjusted odds ratios were GC 0.97 (95% CI, 0.65-1.46) and CC 0.24 (95% CI, 0.05-1.11). Risk associated with the –765G > C variant differed by aspirin or other nonsteroidal anti-inflammatory drug (NSAID) use. Among nonusers of aspirin or other NSAIDs, the CC genotype conferred a significant decrease in risk of adenoma (OR, 0.26; 95% CI, 0.07-0.89). Use of aspirin or other NSAIDs reduced risk of adenoma only among those with the –765GG (wild type) and possibly –765CG genotypes (OR, 0.66; 95% CI, 0.48-0.92 and OR, 0.64; 95% CI, 0.40-1.02, respectively). These data suggest that COX-2 expression or activity may be beneficially suppressed, and risk of colorectal polyps reduced, by aspirin or other NSAIDs in PTGS2 –765GG (wild type) individuals and by the –765 CC variant genotype in nonusers of NSAIDs.
This article has been cited by other articles:
|
|
 |
|
  Y. S. Kim, M. R. Young, G. Bobe, N. H. Colburn, and J. A. Milner Bioactive Food Components, Inflammatory Targets, and Cancer Prevention Cancer Prevention Research, March 1, 2009; 2(3): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang, J. Gu, X. Lin, H. B. Grossman, Y. Ye, C. P. Dinney, and X. Wu Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition Clin. Cancer Res., April 1, 2008; 14(7): 2236 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Tan, J. Wu, X. Zhang, Y. Guo, J. Liu, T. Sun, B. Zhang, D. Zhao, M. Yang, D. Yu, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer Carcinogenesis, June 1, 2007; 28(6): 1197 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, R. J. Kulmacz, J. D. Potter, and C. M. Ulrich Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps Carcinogenesis, June 1, 2007; 28(6): 1259 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. R. Barry, J. A. Baron, S. Bhat, M. V. Grau, C. A. Burke, R. S. Sandler, D. J. Ahnen, R. W. Haile, and T. G. O'Brien Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst, October 18, 2006; 98(20): 1494 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Gunter, F. Canzian, S. Landi, S. J. Chanock, R. Sinha, and N. Rothman Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1126 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Sansbury, A. W. Bergen, K. L. Wanke, B. Yu, N. E. Caporaso, N. Chatterjee, L. Ratnasinghe, A. Schatzkin, T. A. Lehman, A. Kalidindi, et al. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 494 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Correction for vol 14, p 616 Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 3020 - 3020. [Full Text]
|
|
|
|
|
|
M. Macarthur, L. Sharp, G. L. Hold, J. Little, and E. M. El-Omar The Role of Cytokine Gene Polymorphisms in Colorectal Cancer and Their Interaction with Aspirin Use in the Northeast of Scotland Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1613 - 1618. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
